sayeth washington post treating schizophrenia older cheaper drug rather heavily promoted newer medications reduces cost much percent apparent difference safety effectiveness according first study examine economic implications antipsychotic drug prescribing practices united states recent study american journal psychiatry found perphenazine notably less expensive atypical antipsychotics earlier research shown older drug safe effective newer medications experts cautioned assuming cheaper drug would cost effective hospitalizations side effects quality life issues taken account new study published today american journal psychiatry concluded factors included monthly costs per patient lower drug perphenazine longer patent snip indication widespread unease psychiatric establishment results one senior doctor helped conduct study cost effectiveness assessment said new finding faced stiff headwinds published subjected extraordinary level review saying perphenazine cheaper said doctor spoke condition anonymity sensitivity issue explain many psychiatrists weighing study seemed aghast physicians feel defensive people ask 'why charging patient insurance company drugs give anything i join many others including study authors stated mean everyone switch atypical antipsychotics older antipsychotic meds treatment course flexible vary patient response along slew findings like indicate rather clearly medication algorithm necessarily start prescribing atypical antipsychotic medication know one set drugs generally safe case unsafe effective much less expensive another class drugs implications pretty clear right i hope hear extraordinary review process article subjected course results favored newer meds would standard minimal review